The overall validity of biomarkers in the diagnosis of obstructive sleep apnea (OSA) remains unclear. We conducted a scoping review to provide assessments of biomarkers characteristics in the context of obstructive sleep apnea (OSA) and to identify gaps in the literature. A scoping review of studies in humans without age restriction that evaluated the potential diagnostic value of biological markers (blood, exhaled breath condensate, salivary, and urinary) in the OSA diagnosis was undertaken. Retained articles were those focused on the identification of biomarkers in subjects with OSA, the latter being confirmed with a full overnight or home-based polysomnography (PSG). Search strategies for six different databases were developed. The methodology of selected studies was classified using an adaptation of the evidence quality criteria from the American Academy of Pediatrics. Additionally the biomarkers were classified according to their potential clinical application. We identified 572 relevant studies, of which 117 met the inclusion criteria. Eighty-two studies were conducted in adults, 34 studies involved children, and one study had a sample composed of both adults and children. Most of the studies evaluated blood biomarkers. Potential diagnostic biomarkers were found in nine pediatric studies and in 58 adults studies. Only nine studies reported sensitivity and specificity, which varied substantially from 43% to 100%, and from 45% to 100%, respectively. Studies in adults have focused on the investigation of IL-6, TNF-a and hsCRP. There was no specific biomarker that was tested by a majority of authors in pediatric studies, and combinatorial urine biomarker approaches have shown preliminary promising results. In adults IL-6 and IL-10 seem to have a favorable potential to become a good biomarker to identify OSA.
Introduction
Obstructive sleep apnea (OSA) has now been widely recognized as a major public health concern with numerous and widespread societal consequences that include among others, motor vehicle accidents, increased cardiovascular morbidity, heightened risk for metabolic dysfunction, and mood, behavioral and cognitive deficits leading to impaired work performance and productivity [1] . Although healthcare costs are not normally distributed, i.e., the costliest and the sickest tertile of patients consume 65e82% of all medical-related costs, it has now become apparent that OSA significantly adds to the healthcare cost burden, in addition to its adverse impact on the economy [2, 3] . It is notable that sleep disorders have been assigned as playing a causative role in an estimated 9.1% of work-related injuries [4] .
The prevalence of OSA varies widely, ranging from 14.7% to 36.5%, depending on gender and nationality [5] . It is higher in males (34.2%) than in females (14.7%) [5] . Although the prevalence of OSA in Hispanics (36.5%) is similar to American Whites (33.3%), increased risk of OSA occurs in both African American and Asian ethnic groups [5e8] . In contrast, the prevalence of pediatric OSA is reported to be between 1 and 4%, with the caveat that prospective community-based studies using overnight polysomnography (PSG) are lacking [9, 10] .
The standard diagnostic procedure for establishing the presence of OSA is the overnight polysomnography [11] . Except for the a priori reported consensus [11] , an original publication or study that provided definitive validation on the use of overnight PSG as the gold standard in OSA diagnosis could not be found even after an extensive literature search. However, notwithstanding the great progress in our understanding of sleep disorders that PSG have afforded over the years, it has also become apparent that overnight PSG are onerous and labor-intensive tests that impose substantial inconvenience to the patients, and are relatively inaccessible. Indeed, waiting times between referral for evaluation to diagnosis commonly take 3e6 mo across the United States and around the world [12] .
The relative complexity and high costs associated with overnight PSG as the gold standard approach employed for diagnosing the vast majority of sleep disorders has spurred the quest for alternative diagnostic methods [12] . The development of simple, cheap, and reliable screening tools that permit precise screening of at-risk populations is paramount. If accurate identification of those subjects with or without definitive disease is accomplished using such simplified and less onerous tools, then timely access to clinical care would be possible to a large sector of the population [12] .
During the search for this elusive screening tool, special interest has centered around potential OSA biomarkers. The ideal biomarker should be highly sensitive and specific for OSA, should be dose-responsive and correlate to severity of disease, and should be involved in an important causal pathway, so that changes in the biomarker levels reliably predict improvements in the outcome [13] . Several different OSA biomarkers have been proposed over the last 14 y. However, to the best of our knowledge, no scoping review has been conducted thus far to critically examine what we currently know on the potential viability and use of biomarkers in OSA diagnosis and management. Therefore, the purpose of this study was to map our current understanding regarding biomarkers, and provide assessments of their characteristics in the context of OSA in both adults and children, to identify gaps in the research and help with the dissemination of the findings, and to determine the value of conducting a full systematic review related to this topic.
Methods
This scoping review was done adhering to Arksey and O'Malley's scoping review proposed reporting framework [14] .
Research question
A scoping review of studies in humans without age restriction that evaluated the potential diagnostic value of biological markers (blood, exhaled breath condensate (EBC), salivary, and urinary) in the diagnostic process of OSA syndrome was undertaken.
Identification of relevant studies

Inclusion criteria
Retained articles were only those studies whose objective was to identify associated biomarkers in subjects with OSA, the latter being confirmed with a full overnight PSG or home-based PSG. Only studies that performed PSG in all subjects were included. The selected studies could include studies in obese and cardiac patients. Studies that assessed the impact of treatment were also included. Studies with and without a control group were selected. Only studies in English, Spanish and Portuguese language were considered.
Exclusion criteria
Studies using day PSG or multichannel polygraphy as the reference diagnostic standard were not included. Studies using biomarkers only to detect the presence of OSA-associated morbidities (cognitive, excessive sleepiness, cardiovascular, metabolic) and/or in which the sample included genetic syndromic patients (e.g., Down syndrome, craniofacial anomalies, neuromuscular disorders, etc.), or a cohort of patients with a primary disease for which OSA prevalence is being investigated (e.g., patients with kidney disease, and/or rheumatologic conditions) were omitted. Reviews, letters, conference abstracts and personal opinions were not considered.
Detailed individual search strategies for each of the following bibliographic databases were developed: Cochrane, Embase, MEDLINE, PubMed, and LILACS. A partial grey literature search was undertaken using Google Scholar. The end search date for all database searches was March 20, 2014 . The references cited in the selected articles were also checked for any citation that could have been missed during the electronic database searches. Additional studies were obtained from a well-published expert in sleep medicine.
Appropriate truncation and word combinations were selected and were adapted for each database search (Appendix 1). All references were managed by reference manager software (RefWorks-COS is a business unit of ProQuest, LLC.
Study selection
The selection was completed in two phases. In phase 1, two reviewers independently reviewed the titles and abstracts of all identified electronic database citations (GDL and CPP). A third author was involved when required to make a final decision (SA). Any studies that appeared not to fulfill the inclusion criteria were discarded. In phase 2, the same selection criteria were applied to the full articles to confirm their eligibility. The same two reviewers (GDL and CPP) independently participated in phase 2. The reference list of all included articles was reviewed by one examiner (GDL). The articles selected were read by both examiners (GDL and CPP). Any disagreement in either phase was resolved by discussion and mutual agreement between the three reviewers (GDL, CPP, SA). A fourth author with extensive professional experience in sleep medicine (DG) was involved when controversy arose before making a final decision. Final selection was always based on the full-text of the publication.
Abbreviation
AAP
Charting the data
For all included studies the following information was recorded: year of publication, author, country, sample size, age, name and type of biomarkers, diagnostic PSG-based measure, results, and main conclusion. Authors of potentially eligible full-articles were contacted as necessary to provide further details about their studies.
One author (GDL) collected the required information from the selected articles. A second author (CPP) cross-checked all the collected information. Again, any disagreement in either phase was resolved by discussion and mutual agreement between the three reviewers (GDL, CPP, SA). A fourth author (DG) was involved, when required, to make a final decision.
Level of evidence
The methodology of selected studies was classified using a nonvalidated adaptation of the evidence quality criteria from American Academy of Pediatrics (AAP) [11] . Two reviewers (GDL and CPP) independently classified the studies into A (well-designed prognostic or diagnostic studies on relevant population), B (prognostic or diagnostic studies with minor limitations, overwhelmingly consistent evidence from observational studies), and C (observational studies (case-control and cohort design). Disagreements were resolved by a third reviewer (DG).
Additionally the biomarker clinical application was classified as 1) potential diagnostic biomarker(s) 2) when the evidence was inconclusive for diagnostic biomarker, and 3) if the evidence was not supportive as potential diagnostic biomarker(s). Two reviewers (GDL and CPP) independently classified the clinical application of biomarkers. A third reviewer (SA) reviewed the classification. Disagreements were resolved by a fourth reviewer (DG).
Collating, summarizing and report the results Any outcome measurement was considered: risk ratio (RR), odds ratio (OR) or risk difference for dichotomous outcomes; mean difference or standardized mean difference for continuous outcomes; sensitivity and specificity in diagnostic studies.
Results
Study selection
In phase 1, we found 572 citations across the five electronic databases. After duplicate articles were removed, 279 remaining different citations were retained. A comprehensive evaluation of the abstracts was performed and resulted in a final number of 104 articles after phase 1. We found 40 citations in Google Scholar, but only four articles from Google Scholar met our phase 1 inclusion criteria. We identified 29 additional studies from the hand-search of reference lists of these studies, and added six more articles received by an expert (DG). Therefore, we retrieved 143 articles to conduct a full-text review, and subsequently excluded 26 studies [15e40] (Appendix 2). Thus, a total of 117 articles were selected. A flow chart of the process of identification, inclusion, and exclusion of studies is shown in Fig. 1 .
Study characteristics
The selected studies were grouped into two categories: studies involving children (18 years of age) and adults (>18 years of age). Eighty-two studies were conducted in adults and 34 studies involved children (with the exception of one study that included individuals between 12 and 22 years old [41] ). One study had a sample composed of both adults and children [42] .
The pediatric studies were published between 2002 and 2014. (Fig. 2) The diagnostic criterion for OSA was established based on the apnea index (AI), apnea/hypopnea index (AHI), obstructive apnea index (OAI), obstructive apneaehypopnea index (OAHI), and respiratory disturbance index (RDI). Occasionally, the specific PSG measure used to reach the diagnosis of OSA was not reported [61, 64] . When the authors used AHI, the AHI ranged from AHI >1 to AHI >5/hrTST. Most of the studies assessed blood biomarkers [41e44,46,49e52,54e57,59e62,66e68,74], while seven studied urinary biomarkers [47, 48, 53, 58, 63, 64, 73] , four explored for potential biomarkers in saliva [69e72], and three studies involved EBC [45, 65, 75] . A summary of the study descriptive characteristics can be found in Table 1 [103, 104] , and two explored for biomarkers in EBC [149, 150] , while only one study examined saliva [112] . Five studies used both blood and urine [77,151e154] and four studies used blood and EBC [78,155e157] . A summary of the study descriptive characteristics can be found in Table 2 . Complementary information regarding these studies is reported in Appendix 4.
Level of evidence
In studies involving children, nearly all studies were classified as B (prognostic or diagnostic studies with minor limitations, overwhelmingly consistent evidence from observational studies). Only one study [44] was classified as C (case-control and cohort design). 
Table 1
Summary of study descriptive characteristics of included pediatric articles (n ¼ 35). The biomarker clinical application was classified as 1) potential diagnostic biomarker(s) 2) inconclusive for diagnostic biomarker, and 3) evidence not supportive as potential diagnostic biomarker(s). The level of evidence was classified in A (well designed prognostic or diagnostic studies on relevant population), B (prognostic or diagnostic studies with minor limitations, overwhelmingly consistent evidence from observational studies), C (observational studies (case-control and cohort design)). No study was classified as A (well designed prognostic or diagnostic studies on relevant population).
In adult-based studies, 70 were classified as B, with 11 studies being classified as C. Only three studies were classified as fulfilling A criteria [91, 131, 143] .
Synthesis of results
When biomarkers were classified according to their clinical application, the biomarkers studied in nine pediatric studies were designated as potential diagnostic biomarkers; in 15 studies, findings were inconclusive for a diagnostic biomarker, and eight studies presented evidence that was not supportive as potential diagnostic biomarkers. Three studies had different classifications for two biomarkers studied. The classification for each study is presented in Table 1 . All potential biomarkers for pediatric OSA are presented in Table 3 .
In studies involving adults, classification of the biomarkers according to their clinical application yielded 58 studies where the biomarkers were considered as potential diagnostic biomarkers, while 19 studies were inconclusive for diagnostic biomarkers, and three studies presented evidence not supportive as potential diagnostic biomarkers. One study had different classifications for two biomarkers concomitantly studied. Regarding the potential diagnostic biomarkers, interleukin-6 (IL-6), tumor necrosis factor a (TNF-a) and high sensitivity C-reactive protein (hsCRP) were the most frequently assessed biomarkers. The classification for each study is presented in Table 1 . The potential biomarkers for adults identified are shown in Table 4 .
Discussion
The present scoping review investigated the available evidence regarding biomarkers for the diagnosis of OSA. The gold standard for OSA-PSG-imposes several important limitations, such as cost and reduced widespread availability. Moreover, this technique is potentially inconvenient since it requires that the patient will sleep outside the home environment [158] . Therefore, we need to develop methods that would allow for the large-scale screening of at-risk populations, and enable the accurate identification of the subjects with or without the disease, could potentially revolutionize the field [12] . This pressing need to find an ideal biomarker for OSA as an alternative to the PSG may account for the large number of studies that have addressed this topic since 2000. In addition, the realization that OSA is associated with elevated levels of biochemical or inflammatory markers that may contribute to an increased risk of cardiovascular disease further propelled the field forward in the quest for diagnostic biomarkers [128] .
The ideal biomarker should have some critical characteristics, such as disease specificity, mandatory presence in all affected patients (i.e., high sensitivity and specificity), reversibility following proper treatment, and detectability before patients develop obvious clinical manifestations. Furthermore, ideal biomarkers should reflect not only the severity of the disease, but also provide indicative information over the cumulative history of the disease, as well as enable a cut-off value with minimal overlap between normal and disease [159] . In addition, an optimal diagnostic policy employing biomarkers would be expected to minimize the total cost and burden of diagnosing a patient, in which the economic value would consist of the sum of two financially-driven components, namely measurement costs and the costs associated with misdiagnosis [160] .
Before we discuss the actual findings of this scoping review, some technical and methodological considerations regarding the *All terms that mean obstructive sleep apnea (SDB, SRDB, OSAS) were standardized as OSA.
Abbreviations [143] . Most studies were classified as level of evidence B, because they used samples from sleep laboratories or patients with suspected OSA rather than community-based approaches.
In the context of the properties of potential diagnostic biomarkers, the importance of reporting receiver operator curves and other measures of diagnostic performance can not be overemphasized [158] . However, even though it is impossible to properly assess the real diagnostic capability of any alternative test without such measures, we found only nine studies that reported sensitivity and specificity. The sensitivity and specificity for these nine studies [ In summary, this review provides up-to-date insights of the current state of knowledge about biological markers and their potential applicability in OSA diagnosis. Over the last 14 years, a substantial number of studies have aimed to identify an ideal biomarker or set of biomarkers for OSA. Although, no simple and useful disease marker panel for OSA is currently available and routinely used in clinical practice, considerable progress has been Fig. 3 . Distribution of adults' studies according to country (n ¼ 83). China (n ¼ 12), United States (n ¼ 12), Japan (n ¼ 11), Greece (n ¼ 8), Turkey (n ¼ 8), Spain (n ¼ 6), Brazil (n ¼ 3), UK (n ¼ 3), Germany (n ¼ 2), South Korea (n ¼ 2), Taiwan (n ¼ 2). In the following countries only one study was done: Arabia, Australia, Canada, France, India, Ireland, Israel, Israel/ Sweden, Italy, Poland, Portugal, Sweden, Switzerland, Thailand. These countries are not represented in the graph.
Table 2
Summary of study descriptive characteristics of included articles (adults, n ¼ 83) The biomarker clinical application was classified as [1] potential diagnostic biomarker(s) [2] ; inconclusive for diagnostic biomarker, and [3] evidence not supportive as potential diagnostic biomarker(s). The level of evidence was classified in A (well designed prognostic or diagnostic studies on relevant population), B (prognostic or diagnostic studies with minor limitations, overwhelmingly consistent evidence from observational studies), C (observational studies (case-control and cohort design)). made, thereby justifying efforts to provide a critical appraisal of this field, and further indicate future research directions that rely on the cumulative evidence presented heretofore [159] . We should emphasize that despite our comprehensive search strategy, 29 studies were found by hand-searching in the reference list, and that the absence of universally agreed upon PSG criteria for the 2014 Vavougios et al. [148] Greece OSA (n ¼ 120/100 male) Adiponectin,IL-10, IL-8, PAI-1, S100B, TRX, Urinary catecholamines, VEGF, uric acid 2 8-OHdG, Arterial lactate levels, Brachial-ankle PWV, Chemerin, CK, Cystatin C, Cysteine, DJ-1, E-selectin, eCO, eNO, Epinephrine, Fractalkine, GSH, GSSG, H2O2, Homocysteine, L-selectin, LTB4, MCP-1, MMP-9, NF-kB, Nitrates, nNO, Noradrenaline, Norepinephrine, NOx, NSE, Ometin-1, P-selectin, PDW, pLOX-1RDW, S100A12, SAA, slL-R, sTNFR-1, TNF-a receptor 2, VCAM-1, YKL-40. diagnosis of OSA along with the systematic inclusion of patient referral populations may further alter any conclusions pertaining to the validity of a proposed set of promising biomarkers. Notwithstanding such concerns, the cumulative data support the concept that biological markers should provide valid tools to identify OSA in both children and adults, even if a specific set of biomarkers cannot be firmly recommended at this preliminary stage of discovery and validation.
Conclusions
The majority of pediatric studies have been performed in the USA and Greece, while adult studies were primarily conducted in China, USA and Japan. Most of studies used blood biomarkers. Studies in adults primarily explored the investigation of IL-6, TNF-a, and hsCRP as potentially promising biomarkers. There was not a specific biomarker that was tested by a majority of authors in pediatric studies, i.e., each paper evaluated different non-overlapping types of biomarkers.
Only the combination of kallikrein-1, uromodulin, urocortin-3 and orosomucoid-1 appears to provide sufficient accuracy to be considered a potential OSA diagnostic test in children. In adults, IL-6 and IL-10 appear to exhibit a favorable profile as biomarkers aiming to discriminate patients with and without OSA.
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Practice points
The present scoping review shows that: 1) Although there are a substantial number of studies published in the literature, most of the explored approaches do not identify definitive biomarkers.
2) The combination of kallikrein-1, uromodulin, urocortin-3 and orosomucoid-1 appears to have sufficient accuracy to be considered an OSA diagnostic test in children. 3) IL-6 and IL-10 exhibit favorable potential to become a good biomarker to identify OSA and non-OSA adults.
Research agenda
In the future we need to:
1) Improve the reporting methodology by calculating and reporting sensitivity and specificity, using samples from community, and employing a definitive AHI cut-off value for PSG-based diagnosis of OSA. 2) Prepare systematic review and meta-analysis to critically evaluate the diagnostic value of biomarkers in OSA diagnosis. 3) Estimate cost-effectiveness of biomarkers tests. 4) Formulate potential future exploratory research directions and unbiased discovery approaches aiming at advancing this promising area.
* The most important references are denoted by an asterisk.
